← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Molecular Express, Inc.
Rancho Dominguez, CA
$38,601,720
Total funding
53
Grants
Funding over time
peak $6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,601,720 · 53
By mechanism
R44$13,452,491 · 6
R43$9,956,187 · 26
N44$4,294,431 · 2
N01$3,950,371 · 4
N43$2,867,342 · 7
U01$2,388,206 · 1
Investigators at Molecular Express, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
VESIVAX TLR7 FORMULA$2,999,352
N01 · FY2024 · AI
Design and Engineering of VesiVax HIV Immunogen Formulations$1,999,866
N44 · FY2024 · AI
Development of a VesiVax HIV Vaccine Formulation$1,994,571
N44 · FY2022 · AI
Non-Viral Pandemic Influenza Vaccine Development$1,387,125
U01 · FY2007 · AI
Development of a novel SP-B peptide lung surfactant$1,051,147
R44 · FY2014 · HL
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS$1,031,789
R44 · FY2022 · HL
Non-Viral Pandemic Influenza Vaccine Development$1,001,081
U01 · FY2008 · AI
Preclinical Development of a ME-1001, a Synthetic Lung Surfactant$999,853
R44 · FY2024 · HL
Preclinical Development of a ME-1001, a Synthetic Lung Surfactant$999,784
R44 · FY2025 · HL
Genital Herpes Vaccine Discovery$992,626
R44 · FY2008 · AI
Genital Herpes Vaccine Discovery$989,544
R44 · FY2009 · AI
Development of a novel SP-B peptide lung surfactant$957,467
R44 · FY2013 · HL
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS$956,889
R44 · FY2021 · HL
Development of a novel SP-B peptide lung surfactant$953,604
R44 · FY2012 · HL
Development of a Vaccine for the Prevention of Pulmonary Aspergillosis$934,456
R44 · FY2017 · AI
The VesiVax® System: Vaccine Development Made Easy$762,253
R44 · FY2016 · AI
The VesiVax® System: Vaccine Development Made Easy$736,747
R44 · FY2017 · AI
Production of a Lung Surfactant SP-B Mimic$625,381
R44 · FY2009 · HL
Evaluation of VesiVax Adjuvant Formulations for HIV Vaccines$599,983
N43 · FY2019 · AI
DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151 for flu vaccines$599,925
N43 · FY2023 · AI